Your SlideShare is downloading. ×
Ibogaine: Treatment Acceptability
Ibogaine: Treatment Acceptability
Ibogaine: Treatment Acceptability
Ibogaine: Treatment Acceptability
Ibogaine: Treatment Acceptability
Ibogaine: Treatment Acceptability
Ibogaine: Treatment Acceptability
Ibogaine: Treatment Acceptability
Ibogaine: Treatment Acceptability
Ibogaine: Treatment Acceptability
Ibogaine: Treatment Acceptability
Ibogaine: Treatment Acceptability
Ibogaine: Treatment Acceptability
Ibogaine: Treatment Acceptability
Ibogaine: Treatment Acceptability
Ibogaine: Treatment Acceptability
Ibogaine: Treatment Acceptability
Ibogaine: Treatment Acceptability
Ibogaine: Treatment Acceptability
Ibogaine: Treatment Acceptability
Ibogaine: Treatment Acceptability
Ibogaine: Treatment Acceptability
Ibogaine: Treatment Acceptability
Ibogaine: Treatment Acceptability
Ibogaine: Treatment Acceptability
Ibogaine: Treatment Acceptability
Ibogaine: Treatment Acceptability
Ibogaine: Treatment Acceptability
Ibogaine: Treatment Acceptability
Ibogaine: Treatment Acceptability
Ibogaine: Treatment Acceptability
Ibogaine: Treatment Acceptability
Ibogaine: Treatment Acceptability
Ibogaine: Treatment Acceptability
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×
Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

Ibogaine: Treatment Acceptability

1,544

Published on

Published in: Health & Medicine
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
1,544
On Slideshare
0
From Embeds
0
Number of Embeds
1
Actions
Shares
0
Downloads
8
Comments
0
Likes
0
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide
  • Presented May 5, 2003, NYC Iboga and Ibogaine Forum.
  • The principal source of ibogaine is in the bark of the root of Tabernanthe iboga.
  • Based on the writing of Link BG & Phelen JC, “On Stigma and Public Health Implications. Columbia University, 2001. <http://www.stigmaconference.nih.gov/papers.html>
  • Transcript

    • 1. Patient Medication Acceptability and Treatment Options:
      • Ibogaine
      • Methadone
      • Buprenorphine
      Howard S. Lotsof DORA WEINER FOUNDATION
    • 2. Background: Drug Control
      • • 1906 Pure Food and Drug Act
      • • 1914 Harrison Narcotic Act
      • • 1970 Controlled Substances Act
    • 3. Background: Methadone
      • • 1937 synthesized by Max Bockmühl and Gustav Ehrhart, I.G. Farbenindustries. Patent issued 1941
      • • 1950 use in treatment of opioid abstinence syndrome established in US
      • • 1964 use in opioid maintenance therapy
    • 4. Methadone molecule
    • 5. Methadone powder
    • 6. Methadone diskets
    • 7. Methadone liquid
    • 8. Background: Buprenorphine
      • • 1965 synthesized by KW Bentley at Rickitt & sons, UK.
      • • 1975 - 1978 DR Jazinski et al. Indicate utility in treating opiate addiction
      • • 1977 - 2003 John Lewis champions analgesic and antiaddictive development
      • • 2000 Drug Addiction Treatment Act authorizes use in opioid maintenance therapy
      • • 2002 FDA approves that use to Reckitt Benckiser
    • 9. Buprenorphine molecule
    • 10. Buprenorphine products manufacturer, Reckitt Benckiser will not make current product photographs available
    • 11. Background: Ibogaine An experimental medication
      • • Botanical source Tabernanthe iboga. Used for 100s of years in African medicine and religion
      • • 1901 ibogaine isolated by Dybowski and Landrin
      • • 1958 molecular structure determined Bartlett et al.
      • • 1962 Lotsof discovers Antiaddictive effects
      • • 1993 - 2003 Mash & Glick develop second generation ibogaine-like drugs
    • 12. Ibogaine molecule
    • 13. Noribogaine Liver transforms ibogaine into noribogaine
    • 14. 18-methoxycoronaridine molecule 18-MC Synthetic molecule
    • 15. Tabernanthe iboga shrub
    • 16. Roots bark contain ibogaine
    • 17. Pharmaceutical ibogaine experimental medication
    • 18. Discovery of antiaddctive effects
      • Methadone
      • NYC
      • 1964
      • Doctors administer to drugs users
      • Ibogaine
      • NYC
      • 1962
      • Drug users administer to drug users
      Buprenorphine Lexington, KY 1975 Pharmaceutical industry/gov. Development
    • 19. Methadone
      • The golden age of Dole and Nyswander
      • 1966 - 1973
    • 20. Drs. Dole and Nyswander ca 1976
    • 21. Early generation methadone patients
      • The program was administered or controlled by doctors in a medical research environment even at the clinic level.
      • Nurses, counselors and patients believed in opioid maintenance therapy and collaborated to make it work. Patients and staff were a team.
      • There was no “us” and “them”. Patients were treated like any other medical patients.
    • 22. Early generation ibogaine patients
      • A full collaboration between academic researchers, pharmaceutical developers and user self-help groups with mutual respect.
      • Equal status between the parties. Users, doctors and drug developers worked together to define the ideal administration paradigm.
      • There was no “us” and “them”. Patients were treated just like any other medical patients, except when they were treated like doctors.
    • 23. Later generation ibogaine patients
      • Drug users are no longer involved as equal participants in ibogaine development.
      • Drug users and self-help groups, no longer affiliated with medical academics or drug developers, lost a level of authority and control.
      • Ibogaine patients are not dependent on clinic administered drugs. Ibogaine providers generally leave the field rather than control or abuse patients. This could change in the future.
    • 24. Later Generation Methadone Patients What’s wrong with methadone today ?
      • Nothing is wrong with methadone.
      • Almost something is wrong with many clinics that administer and provide it to patients.
      • Medical decisions are often not made by medical doctors.
      • Many clinics practice control of patients rather than providing them with ethical medical care.
    • 25. Buprenorphine patients
      • Buprenorphine patients never shared an important role in the development of the drug.
      • The manufacturer and the US government appear to desire that stigma associated with chemical dependence not be attached to buprenorphine.
      • Whether this early generation or later generations of buphrenorphine patients are well treated by the medical community and society will have to be seen.
    • 26. Two important issues in chemical dependence treatment
      • Stigma
      • Discrimination
    • 27. Stigma Focuses attention on the victim
    • 28. Discrimination: Focuses attention on those who produce rejection and exclusion
    • 29. The ibogaine advantage Ibogaine removes the stigmatized condition.
    • 30. Why ibogaine is not available?
      • Industry deems ibogaine not to be profitable.
      • Government, industry and academia chose to place their interest in the development of opiate drugs with which they are familiar.
      • 3. Ibogaine represents a new scientific paradigm to the understanding of addiction.
    • 31. Ibogaine availability proximate to United States
      • St Kitts West Indies
      • Vancouver, BC, Canada
      • Rosarito, Baja, Mexico
    • 32. Ibogaine availability
    • 33. Ibogaine resources The Ibogaine Dossier An internet library http://www.ibogaine.org http://www.ibogaine.desk.nl
    • 34. Manual for Ibogaine Therapy Second Revision Release date Friday, May 9, 2003 http://www.ibogaine.org/manual.html

    ×